JP2010031044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010031044A5 JP2010031044A5 JP2009255329A JP2009255329A JP2010031044A5 JP 2010031044 A5 JP2010031044 A5 JP 2010031044A5 JP 2009255329 A JP2009255329 A JP 2009255329A JP 2009255329 A JP2009255329 A JP 2009255329A JP 2010031044 A5 JP2010031044 A5 JP 2010031044A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nsaid
- phospholipid
- weight
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 12
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- -1 oxaprosene Chemical compound 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- 229960000894 sulindac Drugs 0.000 claims 2
- 230000036269 ulceration Effects 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960000616 diflunisal Drugs 0.000 claims 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960000649 oxyphenbutazone Drugs 0.000 claims 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 229960002895 phenylbutazone Drugs 0.000 claims 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25671100P | 2000-12-19 | 2000-12-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002582987A Division JP4958381B2 (ja) | 2000-12-19 | 2001-12-19 | 胃腸管保護および治療活性増強のためのレシチン油およびｎｓａｉｄｓの製剤を用いる方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010031044A JP2010031044A (ja) | 2010-02-12 |
| JP2010031044A5 true JP2010031044A5 (enExample) | 2011-01-27 |
Family
ID=22973287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002582987A Expired - Fee Related JP4958381B2 (ja) | 2000-12-19 | 2001-12-19 | 胃腸管保護および治療活性増強のためのレシチン油およびｎｓａｉｄｓの製剤を用いる方法および組成物 |
| JP2009255329A Withdrawn JP2010031044A (ja) | 2000-12-19 | 2009-11-06 | 胃腸管保護および治療活性増強のためのレシチン油およびｎｓａｉｄｓの製剤を用いる方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002582987A Expired - Fee Related JP4958381B2 (ja) | 2000-12-19 | 2001-12-19 | 胃腸管保護および治療活性増強のためのレシチン油およびｎｓａｉｄｓの製剤を用いる方法および組成物 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1343529B1 (enExample) |
| JP (2) | JP4958381B2 (enExample) |
| KR (1) | KR100884493B1 (enExample) |
| CN (2) | CN1543358A (enExample) |
| AT (1) | ATE414542T1 (enExample) |
| AU (1) | AU2001297778B2 (enExample) |
| BR (1) | BR0116380A (enExample) |
| CA (1) | CA2431606C (enExample) |
| CY (1) | CY1110474T1 (enExample) |
| DE (1) | DE60136647D1 (enExample) |
| DK (1) | DK1343529T3 (enExample) |
| ES (1) | ES2317873T3 (enExample) |
| IL (2) | IL156361A0 (enExample) |
| MX (1) | MXPA03005550A (enExample) |
| PT (1) | PT1343529E (enExample) |
| SI (1) | SI1343529T1 (enExample) |
| WO (1) | WO2002085414A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534241C (en) | 2003-07-31 | 2012-05-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
| US20050176809A1 (en) * | 2004-02-05 | 2005-08-11 | Rodlen Laboratories, Inc. | Method and compositions for treatment of painful disorders |
| WO2005084683A1 (fr) * | 2004-03-03 | 2005-09-15 | MARTINS, José, Araujo | Composition a base de lecithine vegetale, ex. de soja, vitamines du complexe b et d'acide acetylsalicylique, et son utilisation pour la fabrication d'un medicament pour le traitement des maladies neuro-degeneratives |
| AU2005295874B2 (en) * | 2004-10-12 | 2011-01-27 | The Board Of Regents Of The University Of Texas System | Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same |
| GB0517673D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| CA2626579A1 (en) * | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| MX2009000658A (es) | 2006-07-19 | 2009-01-30 | Univ Texas | Preparaciones de fosfolipidos y componentes farmaceuticos que contienen acido 5-amino salicilico para el tratamiento de una enfermedad inflamatoria del intestino delgado. |
| US20110008396A1 (en) * | 2007-09-20 | 2011-01-13 | Rutgers, The Sate University Of New Jersey | Compositions and methods for treating cardiovascular conditions |
| GB2477590A (en) * | 2010-02-05 | 2011-08-10 | Biocopea Ltd | A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier |
| DK2629779T3 (en) * | 2010-10-22 | 2017-10-02 | Dr Reddy's Laboratories Sa | Use of stock stable viscous phospholipid depot for wound treatment |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| JP2014507429A (ja) * | 2011-02-04 | 2014-03-27 | バイオコピア リミテッド | 心血管疾患の治療のための組成物および方法 |
| WO2013022410A2 (en) | 2011-08-08 | 2013-02-14 | Mahmut Bilgic | Production method for effervescent formulations comprising dexketoprofen |
| CN103957888B (zh) | 2011-09-29 | 2017-11-21 | PLx 制药公司 | 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用 |
| EP2999487A1 (en) * | 2013-05-23 | 2016-03-30 | Neurosn, Inc. | Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide |
| US9446056B2 (en) * | 2014-02-11 | 2016-09-20 | Dr. Reddy's Laboratories Ltd. | Parenteral compositions of celecoxib |
| CN103908454B (zh) * | 2014-04-17 | 2016-08-24 | 兆科药业（广州）有限公司 | 一种药物组合物及其制备方法和应用 |
| WO2016094617A1 (en) * | 2014-12-11 | 2016-06-16 | Phosphorex, Inc. | Aqueous topical drug formulation with controlled release and increased stability |
| CN104739843A (zh) * | 2015-04-15 | 2015-07-01 | 郭志标 | 一种用于治疗口腔溃疡的药物组合物 |
| AU2019231699B2 (en) * | 2018-03-07 | 2023-03-09 | Andrew Xian Chen | Aqueous formulations for insoluble drugs |
| CN108542909B (zh) * | 2018-03-30 | 2020-07-07 | 浙江海昶生物医药技术有限公司 | 一种阿司匹林磷脂固化组合物、其制备方法及药物制剂 |
| JP7229012B2 (ja) * | 2018-12-25 | 2023-02-27 | 小林製薬株式会社 | 内服用医薬組成物 |
| WO2021195319A1 (en) | 2020-03-26 | 2021-09-30 | Plx Opco Inc. | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME |
| CN120643509B (zh) * | 2025-08-18 | 2025-12-05 | 杭州市滨江区浙医二院经血管植入器械研究院 | 血管内长效留存的油相药物溶液及液体灌注球囊传递方式 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60208910A (ja) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
| US5154930A (en) * | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
| US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| DK0625898T3 (da) * | 1992-02-12 | 1996-06-03 | Janssen Cilag S P A | Liposom-piroxicamformuleringer |
| ATE218872T1 (de) * | 1995-01-27 | 2002-06-15 | Univ Texas | Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen |
| US5955451A (en) * | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
-
2001
- 2001-12-19 AU AU2001297778A patent/AU2001297778B2/en not_active Expired
- 2001-12-19 DE DE60136647T patent/DE60136647D1/de not_active Expired - Lifetime
- 2001-12-19 AT AT01273758T patent/ATE414542T1/de active
- 2001-12-19 WO PCT/US2001/051605 patent/WO2002085414A2/en not_active Ceased
- 2001-12-19 DK DK01273758T patent/DK1343529T3/da active
- 2001-12-19 SI SI200130899T patent/SI1343529T1/sl unknown
- 2001-12-19 ES ES01273758T patent/ES2317873T3/es not_active Expired - Lifetime
- 2001-12-19 BR BR0116380-9A patent/BR0116380A/pt not_active Application Discontinuation
- 2001-12-19 CN CNA018223834A patent/CN1543358A/zh active Pending
- 2001-12-19 MX MXPA03005550A patent/MXPA03005550A/es active IP Right Grant
- 2001-12-19 PT PT01273758T patent/PT1343529E/pt unknown
- 2001-12-19 JP JP2002582987A patent/JP4958381B2/ja not_active Expired - Fee Related
- 2001-12-19 EP EP01273758A patent/EP1343529B1/en not_active Expired - Lifetime
- 2001-12-19 CA CA2431606A patent/CA2431606C/en not_active Expired - Lifetime
- 2001-12-19 CN CN201110165238.6A patent/CN102258457B/zh not_active Expired - Lifetime
- 2001-12-19 KR KR1020037008167A patent/KR100884493B1/ko not_active Expired - Lifetime
- 2001-12-19 IL IL15636101A patent/IL156361A0/xx unknown
-
2003
- 2003-06-09 IL IL156361A patent/IL156361A/en active IP Right Grant
-
2009
- 2009-02-17 CY CY20091100168T patent/CY1110474T1/el unknown
- 2009-11-06 JP JP2009255329A patent/JP2010031044A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010031044A5 (enExample) | ||
| EA201100483A1 (ru) | Новые пирролидин-2-оны в качестве hdm2 лигандов | |
| EP2449114A4 (en) | NEW LIPID FORMULATIONS FOR THE DELIVERY OF THERAPY AGENTS IN SOLID TUMORS | |
| EP2299997A4 (en) | USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES | |
| RU2008146815A (ru) | Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол т нестероидный противовоспалительный препарат | |
| PT2601962T (pt) | Regime de dosagem de lag-3 para utilização no tratamento de cancro | |
| CA2431606A1 (en) | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity | |
| BRPI0815613A2 (pt) | Composições lipossômicas para administração in vivo de compostos de ácido borônico. | |
| TN2009000451A1 (en) | Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor | |
| MA32904B1 (fr) | Composes de purine | |
| FR2935611B1 (fr) | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes | |
| IN2014DN08886A (enExample) | ||
| EA201300053A1 (ru) | Фосфатсвязывающий препарат для удобного приема | |
| CL2013001459A1 (es) | Compuestos derivados de quinazolincarboxamida azetidina; proceso para prepararlos; composicion farmaceutica que los comprende; set (kit); y su uso para el tratamiento de enfermedades hiperproliferativas tales como cancer, inflamacion, pancreatitis o enfermedad renal, dolor, hiperplasia benigna de piel entre otras. | |
| Cathcart et al. | COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention | |
| EP2301525A4 (en) | TOPICAL IBUPROFEN FORMULATION | |
| IL186374A0 (en) | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders | |
| SA516380264B1 (ar) | (s) -بيرليندول وأملاحه المقبولة صيدلانياً للاستخدام في الدواء | |
| IL196507A0 (en) | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease | |
| ZA200807323B (en) | Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs | |
| UY30284A1 (es) | Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 | |
| RU2011112445A (ru) | Фармацевтическая комбинация, которая содержит 6-диметиламинометил-1-(3-метоксифенил)-циклогексан-1,3-диол и нпвс | |
| RU2016148182A (ru) | (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине | |
| CL2007000836A1 (es) | Uso de compuestos derivados de estrobilurina y/o sus sales fisiologicamente toleradas para preparar un medicamento para el tratamiento y/o prevencion de trastornos del metabolismo del hierro. | |
| EA200500942A1 (ru) | Средство для лечения болезней суставов |